Dr. Sherri Cervantez, M.D.
What this data tells you about Dr. Cervantez
Dr. Sherri Cervantez is a hospice and palliative medicine (internal medicine) physician in San Antonio, TX, with 16 years in practice. Based on federal Medicare data, Dr. Cervantez performed 9,842 Medicare services across 630 unique beneficiaries.
Between the years covered by Open Payments, Dr. Cervantez received a total of $451 from 8 pharmaceutical and/or device companies across 11 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hospice and palliative medicine (internal medicine) physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Cervantez is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 4,400 | $43 | $159 |
| Anti-nausea injection (fosaprepitant) | 2,550 | $0 | $1 |
| BCG treatment for bladder cancer | 834 | $2 | $9 |
| Dexamethasone injection (steroid) | 454 | $0 | $0 |
| Anti-nausea injection (ondansetron/Zofran) | 340 | $0 | $0 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 204 | $83 | $536 |
| Anti-nausea injection (Aloxi/palonosetron) | 180 | $1 | $5 |
| Office visit, established patient (30-39 min) | 139 | $97 | $312 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 90 | $3 | $10 |
| Injection of additional new drug or substance into vein | 88 | $12 | $46 |
| Administration of chemotherapy into vein, 1 hour or less | 76 | $99 | $393 |
| Office visit, established patient, complex (40-54 min) | 62 | $136 | $439 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 58 | $22 | $87 |
| Hospital follow-up visit, high complexity | 56 | $91 | $268 |
| Drug injection, under skin or into muscle | 37 | $11 | $41 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 31 | $56 | $224 |
| Administration of chemotherapy into vein, each additional hour | 31 | $22 | $85 |
| Hospital follow-up visit, moderate complexity | 30 | $62 | $178 |
| Instillation of anti-cancer drug into bladder | 28 | $68 | $256 |
| Initial hospital admission, high complexity | 27 | $132 | $435 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $48 | $181 |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $1 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 18 | $49 | $195 |
| Infusion into a vein for hydration, each additional hour | 15 | $10 | $39 |
| Office visit, established patient (20-29 min) | 15 | $68 | $221 |
| Infusion, normal saline solution , 1000 cc | 15 | $2 | $8 |
| Initial hospital admission, moderate complexity | 14 | $102 | $319 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (56%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hospice and palliative medicine (internal medicine) physician and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Cervantez is a mixed practice specialist, with above-average Medicare volume (top 5% in TX), and speaking/promotional industry engagement, with 16 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Cervantez experienced with pembrolizumab injection (keytruda)?
Does Dr. Cervantez receive payments from pharmaceutical companies?
How do Dr. Cervantez's costs compare to other hospice and palliative medicine (internal medicine) physicians in San Antonio?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology